Comparison of Coronary Artery Calcium Scores Between Patients With Psoriasis and Type 2 Diabetes.

Importance Psoriasis is associated with an increased risk of cardiovascular diseases. Subclinical atherosclerosis in patients with psoriasis has not been compared with other conditions associated with increased cardiovascular risk and more rigorous cardiovascular disease screening, such as type 2 diabetes. Objective To assess the burden of asymptomatic coronary atherosclerosis measured by coronary artery calcium score in patients with moderate to severe psoriasis compared with patients with type 2 diabetes and healthy controls. Design, Setting, and Participants Three single-center, cross-sectional studies were performed in patients recruited from specialty outpatient clinics with moderate to severe psoriasis without type 2 diabetes (recruited from November 1, 2013, through April 31, 2015), patients with type 2 diabetes without psoriasis or other inflammatory diseases (recruited from July 1, 2009, through June 20, 2011), and age- and sex-matched healthy controls without psoriasis, type 2 diabetes, or other inflammatory diseases (recruited from July 1, 2009, through June 20, 2011). Exposures Psoriasis, type 2 diabetes, and healthy control effect on coronary artery calcium score. Main Outcomes and Measures Coronary artery calcium measured by Agatston score. Results A total of 387 individuals participated in the study. Mean (SD) age was 51 (7.7), 52 (8.0), and 52 (8.0) years in the psoriasis, type 2 diabetes, and healthy control cohorts, respectively. There were 64 men (49.6%) in each group, and most patients were white (119 [92.2%], 123 [95.3%], and 128 [99.2%] in the psoriasis, type 2 diabetes, and healthy control cohorts, respectively). Patients with psoriasis had low cardiovascular risk measured by the Framingham Risk Score but had a high prevalence of cardiovascular and cardiometabolic risk factors, similar to patients with type 2 diabetes. In a fully adjusted model, psoriasis was associated with coronary artery calcium (Tobit regression ratio, 0.89; P < .001) similar to the association in type 2 diabetes (Tobit regression ratio, 0.79; P = .04). Likelihood ratio testing revealed incremental value for psoriasis in a fully adjusted model (χ2 = 4.48, P = .03) in predicting coronary artery calcium. Psoriasis was independently associated with the presence of any coronary artery calcium (odds ratio, 2.35; 95% CI, 1.12-4.94) in fully adjusted models, whereas the association of coronary artery calcium with type 2 diabetes was no longer significant after adding body mass index to the model (odds ratio, 2.18; 95% CI, 0.75-6.35). Conclusions and Relevance Patients with psoriasis have increased coronary artery calcium by mean total Agatston scores, similar to that of patients with type 2 diabetes, suggesting that patients with psoriasis harbor high rates of subclinical atherosclerosis beyond adjustment for body mass index. Major educational efforts for patients and physicians should be undertaken to reduce the burden of cardiovascular disease in patients with psoriasis.

[1]  H. Bøtker,et al.  Increased Prevalence of Coronary Artery Disease in Severe Psoriasis and Severe Atopic Dermatitis. , 2015, The American journal of medicine.

[2]  D. Bluemke,et al.  Cholesterol efflux capacity in humans with psoriasis is inversely related to non-calcified burden of coronary atherosclerosis. , 2015, European heart journal.

[3]  T. Torres,et al.  Epicardial adipose tissue and coronary artery calcification in psoriasis patients , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  I. Benseñor,et al.  Association between psoriasis and coronary calcium score. , 2014, Atherosclerosis.

[5]  D. Margolis,et al.  Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study , 2014, Annals of the rheumatic diseases.

[6]  S. Younespour,et al.  Increased serum leptin and resistin levels and increased carotid intima-media wall thickness in patients with psoriasis: is psoriasis associated with atherosclerosis? , 2014, Journal of the American Academy of Dermatology.

[7]  D. Bluemke,et al.  Vascular inflammation in psoriasis localizes to the arterial wall using a novel imaging technique. , 2014, Journal of the American Academy of Dermatology.

[8]  M. Budoff,et al.  Coronary computed tomography as a cost-effective test strategy for coronary artery disease assessment - a systematic review. , 2014, Atherosclerosis.

[9]  E. Mohler,et al.  Endothelial Cell‐, Platelet‐, and Monocyte/Macrophage‐Derived Microparticles are Elevated in Psoriasis Beyond Cardiometabolic Risk Factors , 2014, Journal of the American Heart Association.

[10]  M. Reilly,et al.  Psoriasis is associated with decreased plasma adiponectin levels independently of cardiometabolic risk factors , 2014, Clinical and experimental dermatology.

[11]  L. Arends,et al.  Markers of systemic inflammation in psoriasis: a systematic review and meta‐analysis , 2013, The British journal of dermatology.

[12]  Jashin J. Wu,et al.  Association of ethnicity, tumor necrosis factor inhibitor therapy, and myocardial infarction risk in patients with psoriasis. , 2013, Journal of the American Academy of Dermatology.

[13]  A. Armstrong,et al.  Psoriasis and Major Adverse Cardiovascular Events: A Systematic Review and Meta‐Analysis of Observational Studies , 2013, Journal of the American Heart Association.

[14]  A. Armstrong,et al.  Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. , 2013, Journal of the American Academy of Dermatology.

[15]  C. Siu,et al.  Prevalence and extent of subclinical atherosclerosis in patients with psoriasis , 2013, Journal of internal medicine.

[16]  Rosa Parisi,et al.  Global epidemiology of psoriasis: a systematic review of incidence and prevalence. , 2013, The Journal of investigative dermatology.

[17]  J. Tardif,et al.  Effects of the Tumor Necrosis Factor-&agr; Antagonist Adalimumab on Arterial Inflammation Assessed by Positron Emission Tomography in Patients With Psoriasis: Results of a Randomized Controlled Trial , 2013, Circulation. Cardiovascular imaging.

[18]  A. Armstrong,et al.  The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies , 2012, Nutrition & Diabetes.

[19]  M. Reilly,et al.  Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. , 2012, Atherosclerosis.

[20]  David J. Margolis,et al.  Prevalence of metabolic syndrome in patients with psoriasis: A population-based study in the United Kingdom , 2011, The Journal of investigative dermatology.

[21]  A. Alavi,et al.  Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. , 2011, Archives of dermatology.

[22]  A. Troxel,et al.  Attributable risk estimate of severe psoriasis on major cardiovascular events. , 2011, The American journal of medicine.

[23]  P. Greenland,et al.  Distribution of coronary artery calcium scores by Framingham 10-year risk strata in the MESA (Multi-Ethnic Study of Atherosclerosis) potential implications for coronary risk assessment. , 2011, Journal of the American College of Cardiology.

[24]  D. Federman,et al.  Psoriasis and Vascular Disease—Risk Factors and Outcomes: A Systematic Review of the Literature , 2011, Journal of General Internal Medicine.

[25]  C. Apovian,et al.  Elevated Proinflammatory Cytokine Production by a Skewed T Cell Compartment Requires Monocytes and Promotes Inflammation in Type 2 Diabetes , 2011, The Journal of Immunology.

[26]  M. Budoff,et al.  2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2010, Circulation.

[27]  A. Troxel,et al.  Cause‐specific mortality in patients with severe psoriasis: a population‐based cohort study in the U.K. , 2010, The British journal of dermatology.

[28]  J. Danesh,et al.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies , 2010, The Lancet.

[29]  P. Greenland,et al.  Coronary artery calcium score and risk classification for coronary heart disease prediction. , 2010, JAMA.

[30]  Andrea B Troxel,et al.  Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. , 2010, European heart journal.

[31]  A. Troxel,et al.  The risk of stroke in patients with psoriasis. , 2009, The Journal of investigative dermatology.

[32]  D. Federman,et al.  Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. , 2009, Archives of dermatology.

[33]  K. Ley,et al.  Immune and inflammatory mechanisms of atherosclerosis (*). , 2009, Annual review of immunology.

[34]  C. Becker,et al.  Predictive value of coronary calcifications for future cardiac events in asymptomatic patients with diabetes mellitus: A prospective study in 716 patients over 8 years , 2008, BMC cardiovascular disorders.

[35]  S. Humphries,et al.  Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the PREDICT study. , 2008, European heart journal.

[36]  Steven R Feldman,et al.  Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. , 2008, Journal of the American Academy of Dermatology.

[37]  R. Kronmal,et al.  Coronary calcium as a predictor of coronary events in four racial or ethnic groups. , 2008, The New England journal of medicine.

[38]  C. Herzog,et al.  Psoriasis: a possible risk factor for development of coronary artery calcification , 2007, The British journal of dermatology.

[39]  Daniel B. Shin,et al.  Prevalence of cardiovascular risk factors in patients with psoriasis. , 2006, Journal of the American Academy of Dermatology.

[40]  D. Margolis,et al.  Risk of myocardial infarction in patients with psoriasis. , 2006, JAMA.

[41]  L. Shaw,et al.  Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy. , 2006, European heart journal.

[42]  Fernando Costa,et al.  Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. , 2005, Circulation.

[43]  A. Localio,et al.  Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. , 2004, The Journal of clinical endocrinology and metabolism.

[44]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[45]  R. Seibel,et al.  Comparison of electron beam computed tomography with intracoronary ultrasound and coronary angiography for detection of coronary atherosclerosis. , 1997, Journal of the American College of Cardiology.

[46]  S. Nomura,et al.  Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. , 1995, Atherosclerosis.

[47]  R. Detrano,et al.  Quantification of coronary artery calcium using ultrafast computed tomography. , 1990, Journal of the American College of Cardiology.

[48]  P. Calabresi,et al.  Psoriasis and occlusive vascular disease , 1978, The British journal of dermatology.

[49]  J. Tobin Estimation of Relationships for Limited Dependent Variables , 1958 .